Affinity Asset Advisors LLC Cuts Holdings in Karyopharm Therapeutics Inc. $KPTI

Affinity Asset Advisors LLC lowered its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 43.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 500,000 shares of the company’s stock after selling 389,575 shares during the period. Affinity Asset Advisors LLC’s holdings in Karyopharm Therapeutics were worth $2,785,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in KPTI. Renaissance Technologies LLC raised its holdings in Karyopharm Therapeutics by 75.9% in the first quarter. Renaissance Technologies LLC now owns 105,414 shares of the company’s stock valued at $587,000 after acquiring an additional 45,500 shares in the last quarter. Hsbc Holdings PLC acquired a new position in shares of Karyopharm Therapeutics during the first quarter worth $66,000. Corient Private Wealth LLC acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter worth $74,000. T. Rowe Price Investment Management Inc. grew its stake in shares of Karyopharm Therapeutics by 112.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock worth $10,977,000 after purchasing an additional 790,417 shares in the last quarter. Finally, Ikarian Capital LLC increased its holdings in Karyopharm Therapeutics by 1,897.9% in the fourth quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock valued at $4,008,000 after buying an additional 517,297 shares during the last quarter. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Price Performance

Karyopharm Therapeutics stock opened at $7.41 on Friday. The stock’s 50 day moving average price is $9.05 and its 200 day moving average price is $8.26. Karyopharm Therapeutics Inc. has a 1-year low of $3.65 and a 1-year high of $10.99. The company has a market cap of $167.91 million, a PE ratio of -0.49 and a beta of 0.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.21. The business had revenue of $35.07 million during the quarter, compared to analysts’ expectations of $31.40 million. On average, equities research analysts anticipate that Karyopharm Therapeutics Inc. will post -3.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on KPTI. Piper Sandler restated an “overweight” rating and issued a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a research note on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a report on Thursday, June 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $16.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.67.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.